Dutch pension fund dumps Mylan on worries about death penalty drug

Europeans have had a bone to pick with companies supplying death penalty drugs to U.S. prisons, with government officials restricting exports and prompting shortages. In the latest chapter of the saga, a Dutch pension fund is selling out of Mylan ($MYL) after discovering that one of its products is stocked at a U.S. prison that carries out executions. More from FiercePharma

Suggested Articles

A few years ago, one of our Fierce editors met a Big Pharma R&D chief for the first time. “You’re the ones with the scary name,” he joked.

Novartis is touting 52-week data for Cosentyx in spondyloarthritis—an indication where Eli Lilly's Taltz recently scored a trailblazing FDA approval.

Bristol Myers Squibb's Zeposia will leverage promising top-line phase 3 data into a possible FDA approval in the lucrative ulcerative colitis market.